Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4485 Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms (NEN) treated with [177Lu]Lu-DOTA-Octreotate (LuTate) therapy over a 4.5 year period at a single high volume treatment centre

Introduction: LuTate therapy is an effective treatment for patients with somatostatin receptor expressing NEN. However, patients (pts) with functional tumours may develop an acute flare of symptoms during or after PRRT.

Conference:

Presenting Author: Kong G

Authors: Neeson L, Boehm E, Chiang C, Michael M, Sachithanandan N,

Keywords: PRRT, NET, high-risk, flare, outcomes, NEN, single centre,

#3823 Added value of post 177Lu Dotatate and Ga PET/CT imaging in prediction and evaluation of treatment response for GEP NETs

Introduction: Theragnostic approach using 68Ga Dota-peptides (PET) for diagnosis and Lutetium-177 Dotatate (Lutate) for therapy is approved in gastroenteropancreatic neuroendocrine tumors (GEP-NET). The 24-hour post-Lutate treatment imaging (Lutate post tp) evaluates the radiotracer distribution.

Conference:

Presenting Author: Abenavoli E

Authors: Abenavoli E, Linguanti F, Briganti V, Antonuzzo L, Mungai F,

Keywords: Lutetium-177 Dotatate, 68Ga-Dota peptide, evaluation response, prediction response, imaging parameter,

#3698 PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma

Introduction: Management of metastatic insulinoma (MI) presents dual management challenges of hypoglycaemia (hypo) and progressive oncologic disease. Case reports describe remarkable responses to PRRT but limited follow-up (FU).

Conference:

Presenting Author: Pattison D

Authors: Pattison D, Kong G, Hofman M, Akhurst T, Ravi Kumar A,

Keywords: Insulinoma, PRRT, hypoglycaemia, [177Lu]Lu-DOTATATE,

#2919 Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II Studies of Lu-Octreotate Peptide Receptor Radionuclide Therapy (LuTate PRRT) +/- Capecitabine, Temozolomide (CAPTEM) or CAPTEM Alone for Neuroendocrine Tumours (NETs

Introduction: Chemotherapy is often combined with PRTT to treat NETs of pancreatic or midgut origin (pNET/mNET) based on the principle of radiosensitization.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Pavlakis N

Authors: Pavlakis N, Ransom D, Wyld D, Sjoquist K, Asher R,

Keywords: Lutate, PRRT, chemotherapy, CAPTEM, NETs,

#2292 PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Brabander T, Kam B, Teunissen J, Krenning E,

Keywords: Salvage, PRRT, Re-treatment, GEP-NET, Safety, Efficacy, 177Lu-DOTATATE,